Literature DB >> 30253703

Behcet's disease and severe inflammatory reaction to 23-valent pneumococcal polysaccharide vaccine: a case report and review of literature.

MohammadMahdi Saeidinejad1, Sally Kardash2, Laura Connell3.   

Abstract

Current European League Against Rheumatism guidelines strongly recommend considering the use of polysaccharide pneumococcal vaccine in all patients with autoimmune inflammatory rheumatic diseases. However, a previously published case series reports of reactions to 23-valent pneumococcal polysaccharide vaccine in patients with Behcet's disease. The purpose of this report is to present a similar case of a systemic adverse reaction in a patient with Behcet's disease to 23-valent pneumococcal polysaccharide vaccine.

Entities:  

Keywords:  Behcet’s disease; inflammatory reaction; pneumococcal vaccine; vasculitis

Year:  2018        PMID： 30253703     DOI： 10.1177/0036933018801215

Source DB:  PubMed          Journal:  Scott Med J        ISSN： 0036-9330            Impact factor:   0.729


  3 in total

1.  Safety of SARS-CoV-2 vaccination in patients with Behcet's syndrome and familial Mediterranean fever: a cross-sectional comparative study on the effects of M-RNA based and inactivated vaccine.

Authors:  Ayse Ozdede; Sabriye Guner; Guzin Ozcifci; Berna Yurttas; Zeynep Toker Dincer; Zeynep Atli; Uğur Uygunoğlu; Eser Durmaz; Didar Uçar; Serdal Uğurlu; Sabahattin Saip; Fehmi Tabak; Vedat Hamuryudan; Emire Seyahi
Journal:  Rheumatol Int       Date:  2022-04-04       Impact factor: 3.580

2.  Diffuse cutaneous reaction following PPV-23 pneumococcal vaccine: an immunisation-associated hypersensitivity vasculitis.

Authors:  Abuelmagd Abdalla; Salim Sebaoui; Shafeeq Alraqi
Journal:  BMJ Case Rep       Date:  2020-03-18

3.  Reactivation in major organ involvement following SARS-CoV-2 mRNA vaccination in Behçet's syndrome patient receiving immunosuppressive therapy.

Authors:  Reşit Yıldırım; Döndü Üsküdar Cansu; Mustafa Dinler; Cengiz Korkmaz
Journal:  Rheumatology (Oxford)       Date:  2022-06-28       Impact factor: 7.046
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.